Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
PTC Therapeutics, Inc. (PTCT)  
$36.36 0.55 (1.54%) as of 4:30 Fri 5/31


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,552,000
Market Cap: 3.29(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $18.07 - $45.015
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 8
Insider 3/6 Months : 8.6
Guru Rank Number :  538
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 7,700 7,700 7,700
Total Buy Value $0 $198,736 $198,736 $198,736
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 1 1
Total Shares Sold 26,156 72,347 85,013 300,515
Total Sell Value $921,768 $2,218,045 $2,727,877 $13,658,321
Total People Sold 4 9 10 16
Total Sell Transactions 6 28 30 90
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 524
  Page 17 of 21  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Almstead Neil Gregory Chief Technical Ops Officer   •       –      –    2019-01-07 4 S $34.75 $6,255 I/I (180) 5,649     -
   Almstead Neil Gregory Chief Technical Ops Officer   •       –      –    2019-01-07 4 S $34.75 $16,437 D/D (473) 17,396     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2018-06-19 4 AS $48.09 $966,240 D/D (20,000) 17,154     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2018-06-19 4 OE $10.85 $217,000 D/D 20,000 37,154     -
   Souza Marcio Chief Operating Officer   •       –      –    2018-06-01 4 S $34.65 $178,829 D/D (5,161) 63,071     -
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2018-01-05 4 S $18.03 $40,207 D/D (2,230) 26,646     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2018-01-05 4 S $18.03 $1,478 I/I (82) 5,125     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2018-01-05 4 S $18.03 $11,197 D/D (621) 17,154     -
   Utter Christine Marie Principal Financial Officer   •       –      –    2018-01-04 4 S $17.67 $7,280 D/D (412) 6,660     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2018-01-04 4 S $17.67 $1,361 I/I (77) 5,207     -
   Souza Marcio Chief Operating Officer   •       –      –    2018-01-03 4 A $0.00 $0 I/I 1,079 1,742     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2018-01-03 4 A $0.00 $0 I/I 874 5,284     -
   Utter Christine Marie Principal Financial OfficerOff   •       –      –    2017-06-02 3 IO $0.00 $0 D/D 0 5,297     -
   Souza Marcio Chief Operating OfficerOfficer   •       –      –    2017-05-31 3 IO $0.00 $0 D/D 0 36,457     -
   Souza Marcio Chief Operating Officer   •       –      –    2017-05-31 4 A $0.00 $0 D/D 30,000 36,457     -
   Rothera Mark Chief Commercial Officer   •       –      –    2017-05-24 4 OE $10.85 $21,700 D/D 2,000 33,739     -
   Graham Dawn Director   –       •      –    2017-05-23 4 B $13.49 $337,230 D/D 25,000 25,000 2.39     -
   Kovacs Shane William Charles Chief Financial Officer   •       –      –    2017-05-09 4 OE $10.85 $108,500 D/D 10,000 37,850     -
   Complete Pharma Holdings Ii, Llc 10% Owner   –       –       •   2017-04-28 4 D $0.00 $0 D/D (6,683,598) 0     -
   Complete Pharma Holdings Ii, Llc 10% Owner   –       –       •   2017-04-20 3 IO $0.00 $0 D/D 0 6,683,598     -
   Rothera Mark Chief Commercial Officer   •       –      –    2017-03-15 4 OE $10.85 $32,181 D/D 2,966 31,739     -
   Rothera Mark Chief Commercial Officer   •       –      –    2017-02-16 4 OE $10.85 $33,906 D/D 3,125 28,773     -
   Rothera Mark Chief Commercial Officer   •       –      –    2017-01-17 4 OE $10.85 $33,906 D/D 3,125 25,648     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2017-01-05 4 S $11.82 $922 I/I (78) 2,687     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2017-01-03 4 A $0.00 $0 I/I 720 2,765     -
  524 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 17 of 21
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us